TORONTO | An application of collective action has been filed against the manufacturer of Elmiron because this drug approved to treat an inflammatory disease of the bladder is believed to result in vision problems.
Elmiron is an oral medication used to treat interstitial cystitis, a chronic bladder disease that can cause pain, bladder, pelvic and urinary tract.
“It is alleged that the use of long-term Elmiron (the polysulfate of pentosan) is linked to vision problems, in particular, to a new, eye disorder progressive, affecting the part of the retina that allows sharp vision,” said Wednesday the law firm Siskinds LLP.
It is this firm that has filed the claim in Ontario in order to obtain the permission to engage in a collective action on behalf of all Canadians. An application has also been filed in Quebec. To be able to go forward in justice, such proceedings must first get the green light from a court.
“Elmiron is used by hundreds of thousands of Canadians in the management of interstitial cystitis, a majority of the women said to Me, Jill McCartney of at Siskinds LLP. Elmiron, which is often used long term, has been associated with a permanent loss of vision. These visual impairments have a significant impact on the quality of life of Canadians who have suffered these injuries. “
The firm alleges that the vision problems eye alleged include blurred vision, poor color perception, difficulty reading and difficulty of adjustment to the brightness.
He argues that “manufacturers of Elmiron were not properly warned users and health professionals that the use of Elmiron increases the risk of loss of vision”.
In the United States of similar requests have also been filed. In a press release published at the beginning of the month, the us law firm, Bronstein, Gewirtz & Grossman alleged “that Elmiron is manufactured by Janssen Pharmaceuticals, under Johnson & Johnson, is aware of the research linking Elmiron to loss of vision for 2018, but has not warned consumers of the dangers.”